Re:Cognition Health Announces Medicare Coverage for FDA-Approved Early-Stage Alzheimer's Disease Treatments at Its Four U.S. Clinics
PR Newswire —
FAIRFAX, Va., Jan. 22, 2026 /PRNewswire/ -- Re:Cognition Health, a clinical research and treatment provider, announced today Medicare coverage for FDA-approved amyloid-targeting medications Leqembi™ (lecanemab) and Kisunla™ (donanemab) is now available for eligible patients when...